TY - JOUR
T1 - Solid, low-attenuation splenic lesions on computed tomography in patients with indolent lymphoma often signal transformation
T2 - A series of ten patients
AU - Welch, John S.
AU - Foyil, Kelley V.
AU - Powers, Michelle L.E.
AU - Middleton, William D.
AU - Bartlett, Nancy L.
PY - 2012/12
Y1 - 2012/12
N2 - Patients with indolent lymphoma have a 30% risk of transformation to aggressive large-cell lymphoma. Clinical signs of transformation include elevated lactate dehydrogenase (LDH) levels, B symptoms, hypercalcemia, unusual extranodal sites, and rapid node growth, but these are not definitive. We present 10 patients with indolent lymphoma with solid low-attenuation lesions in the spleen on computed tomographic scans. Six of these patients were diagnosed with transformed lymphoma based on biopsy results. In patients with indolent lymphoma, hypodense lesions in the spleen should be biopsied to rule out transformation. If biopsy is not feasible, empirical treatment for transformed lymphoma is warranted.
AB - Patients with indolent lymphoma have a 30% risk of transformation to aggressive large-cell lymphoma. Clinical signs of transformation include elevated lactate dehydrogenase (LDH) levels, B symptoms, hypercalcemia, unusual extranodal sites, and rapid node growth, but these are not definitive. We present 10 patients with indolent lymphoma with solid low-attenuation lesions in the spleen on computed tomographic scans. Six of these patients were diagnosed with transformed lymphoma based on biopsy results. In patients with indolent lymphoma, hypodense lesions in the spleen should be biopsied to rule out transformation. If biopsy is not feasible, empirical treatment for transformed lymphoma is warranted.
KW - Indolent
KW - Lymphoma
KW - Spleen
KW - Transformation
UR - http://www.scopus.com/inward/record.url?scp=84869468196&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2012.08.001
DO - 10.1016/j.clml.2012.08.001
M3 - Article
C2 - 22981965
AN - SCOPUS:84869468196
SN - 2152-2650
VL - 12
SP - 452
EP - 454
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 6
ER -